The unfinished business of primary biliary cirrhosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
In nearly every multifactorial human disease, there are three periods that characterize our understanding and definition. First, there is a period in which there is rapid accumulation of descriptive data. Second, there is a longer and slower period as information is obtained that redefines and expands basic and clinical knowledge that lacks the final and important area of understanding aetiology and therapeutic intervention. Third, which is much less common for most diseases, is the vigorous definition of pathobiology and treatment. These phases are well illustrated by our current understanding of primary biliary cirrhosis (PBC). The term PBC was first used nearly 60 years ago and for the first 40 or so years, the primary research efforts were directed at clinical definitions and pathology. Subsequently, with the advent of molecular biology, there began a rigorous dissection of the immune response and, in particular, a better understanding of anti-mitochondrial antibodies. These efforts have greatly helped in our understanding of not only the effector mechanisms of disease, but also the uniqueness of the primary target tissue, biliary epithelium. However, this research has still not led to successful translation for specific therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Self-citationPrognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816 · cited 2×
“This was of particular interest in the comparison with established prognostic scores such as the Mayo score [23].”
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · cited 1×
“Indeed, a complete biochemical response to UDCA as normalization of alkaline phosphatase levels is suggested as a major determinant of UDCA effectiveness on disease progression (31).”
Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621
Self-citationGershwin, M. E., Mackay, I. R., Sturgess, A., & Coppel, R. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.10.3525 · Cited by 557
Self-citationSEROLOGICAL TESTS IN DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS
WALKER, J. (1965) · The Lancet · doi:10.1016/s0140-6736(65)91372-3 · Cited by 507 · cited 1×
“Phase 1 Earlier breakthrough Proof of AMA specificity [94] Established diagnostic criteria [95] Phase 2 Minimizing AMA-negative Use of recombinant antigens [96] Use of multiplex AMA tests [12] Phase 3 What is next? 100% specific histology 100% sensitive AMA tests PBC-diagnostic ANA”
Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment
Selmi, C., Mayo, M. J., Bach, N., Ishibashi, H., Invernizzi, P., Gish, R. G., Gordon, S. C., Wright, H. I., Zweiban, B., Podda, M., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.05.005 · Cited by 480 · cited 1×
“Phase 1 Earlier breakthrough Familial PBC [4] Twin concordance [98] Risk factors [9] Phase 2 Later developments HLA/non-HLA associations [99] X chromosome defects [100] Bacterial candidates [101] Xenobiotic reactivity [56] Phase 3 What is next? Genome-wide association studies Spontaneous animal models Epigenetic studi…”
Self-citationDrug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417 · cited 1×
“UDCA mechanism of action in PBC remains incompletely understood but it has been hypothesized that it is based on several factors, including stimulation of impaired secretion of the bile-acid pool, reduction in proinflammatory cytokines, effects on apoptosis and on vasoactive mediators (27-29).”
Epidemiology and natural history of primary biliary cirrhosis in a U.S. community
Kim, W. R., Lindor, K. D., Locke, G. R., Therneau, T. M., Homburger, H. A., Batts, K. P., Yawn, B. P., Petz, J. L., Melton, L. J., & Dickson, E. R. (2000) · Gastroenterology · doi:10.1053/gast.2000.20197 · Cited by 349
Ranke, M. B., & Saenger, P. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05487-3 · Cited by 345
Patients With Primary Biliary Cirrhosis React Against A Ubiquitous Xenobiotic–Metabolizing Bacterium
Selmi, C., Balkwill, D. L., Invernizzi, P., Ansari, A. A., Coppel, R. L., Podda, M., Leung, P. S., Kenny, T. P., Van De Water, J., Nantz, M. H., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50446 · Cited by 312 · cited 1×
“coli) and its 16S rRNA specific sequences were detected in human fecal samples (52).”
Self-citationInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293 · cited 1×
“We believe this is too narrow as patients lacking serum AMA appear to follow a similar natural history when compared to their AMApositive counterparts [11].”
Self-citationPrince, M. I., Chetwynd, A., Craig, W. L., Metcalf, J. V., & James, O. F. W. (2004) · Gut · doi:10.1136/gut.2003.023937 · Cited by 261 · cited 1×
“Based on these data, it has been hypothesized that survival rates of asymptomatic patients with PBC is shorter than the general population if symptoms develop during follow-up [25] and this may be secondary to non liver related deaths [26].”
IL-2 receptor α−/− mice and the development of primary biliary cirrhosis
Wakabayashi, K., Lian, Z.-X., Moritoki, Y., Lan, R. Y., Tsuneyama, K., Chuang, Y.-H., Yang, G.-X., Ridgway, W., Ueno, Y., Ansari, A. A., et al. (2006) · Hepatology · doi:10.1002/hep.21385 · Cited by 233
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites
Ala, A., Stanca, C. M., Bu-Ghanim, M., Ahmado, I., Branch, A. D., Schiano, T. D., Odin, J. A., & Bach, N. (2006) · Hepatology · doi:10.1002/hep.21076 · Cited by 222 · cited 1×
“PBC epidemiology is often based on different case-finding methods and data are thus difficult to compare, yet the concept of a PBC geoepidemiological pattern has been supported also by anedoctal reports of disease clustering (6,7).”
Odin, J. A., Huebert, R. C., Casciola-Rosen, L., LaRusso, N. F., & Rosen, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200110716 · Cited by 220
Altered Monocyte Responses to Defined TLR Ligands in Patients With Primary Biliary Cirrhosis *
Mao, T. K., Lian, Z.-X., Selmi, C., Ichiki, Y., Ashwood, P., Ansari, A. A., Coppel, R. L., Shimoda, S., Ishibashi, H., & Gershwin, E. M. (2005) · Hepatology · doi:10.1002/hep.20859 · Cited by 185 · cited 2×
“PBC monocytes manifest an increased response to pathogen associated stimuli, as indicated by higher levels of pro-inflammatory cytokines [73].”
Self-citationCharatcharoenwitthaya, P., Pimentel, S., Talwalkar, J. A., Enders, F. T., Lindor, K. D., Krom, R. A. F., & Wiesner, R. H. (2007) · Liver Transplantation · doi:10.1002/lt.21124 · Cited by 179 · cited 1×
“Liver transplantation is the optimal treatment for end-stage PBC [33] despite common recurrence [34] influenced by immunosuppressive regimens and the recipient sex [35].”
Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis
Wesierska-Gadek, J., Penner, E., Battezzati, P. M., Selmi, C., Zuin, M., Hitchman, E., Worman, H. J., Gershwin, E. M., Podda, M., & Invernizzi, P. (2006) · Hepatology · doi:10.1002/hep.21172 · Cited by 177
Self-citationCharacterization of antimitochondrial antibodies in healthy adults
Mattalia, A., Quaranta, S., Leung, P. S. C., Bauducci, M., Van de Water, J., Calvo, P. L., Danielle, F., Rizzetto, M., Ansari, A., Coppel, R. L., et al. (1998) · Hepatology · doi:10.1002/hep.510270303 · Cited by 146 · cited 1×
“Hence, there is the need for rigorous population-based studies in different geographical areas that do not imply selection bias, as in the case of blood donors [8], or solid case-finding methods.”
Quality of life in patients with primary biliary cirrhosis
Poupon, R. E., Chrétien, Y., Chazouillères, O., Poupon, R., & Chwalow, J. (2004) · Hepatology · doi:10.1002/hep.20276 · Cited by 144 · cited 1×
“ing data have been reported on fatigue [15,16] or quality of life impairment [17,18] but their comparisons remain difficult due to social differences and the use of various questionnaires.”
Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis
Springer, J., Cauch-Dudek, K., O'Rourke, K., Wanless, I. R., & Heathcote, E. J. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.00770.x · Cited by 141 · cited 1×
“Based on these data, it has been hypothesized that survival rates of asymptomatic patients with PBC is shorter than the general population if symptoms develop during follow-up [25] and this may be secondary to non liver related deaths [26].”
Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort
Jones, D. E. J., Bhala, N., Burt, J., Goldblatt, J., Prince, M., & Newton, J. L. (2006) · Gut · doi:10.1136/gut.2005.080317 · Cited by 136 · cited 1×
“ing data have been reported on fatigue [15,16] or quality of life impairment [17,18] but their comparisons remain difficult due to social differences and the use of various questionnaires.”
Lazaridis, K. N., Juran, B. D., Boe, G. M., Slusser, J. P., de Andrade, M., Homburger, H. A., Ghosh, K., Dickson, R. E., Lindor, K. D., & Petersen, G. M. (2007) · Hepatology · doi:10.1002/hep.21749 · Cited by 128 · cited 1×
“, ‘familial PBC’) with different prevalence rates [38] and the resulting risk for first-degree relatives of PBC cases to develop the disease [9] or to manifest serum AMA positivity [39].”
Chuang, Y.-H., Lian, Z.-X., Tsuneyama, K., Chiang, B.-L., Ansari, A. A., Coppel, R. L., & Eric Gershwin, M. (2006) · Journal of Autoimmunity · doi:10.1016/j.jaut.2006.04.001 · Cited by 121 · cited 1×
“Similarly, Chuang and colleagues reported a marked increase in the frequency and absolute number of blood and liver NK cells in PBC cases [75].”
Grambsch, P. M., Dickson, R. E., Kaplan, M., Lesage, G., Fleming, T. R., & Langworthy, A. L. (1989) · Hepatology · doi:10.1002/hep.1840100516 · Cited by 107
Cited by
Natural killer cells regulate T cell immune responses in primary biliary cirrhosis
Shimoda, S., Hisamoto, S., Harada, K., Iwasaka, S., Chong, Y., Nakamura, M., Bekki, Y., Yoshizumi, T., Shirabe, K., Ikegami, T., et al. (2015) · Hepatology · doi:10.1002/hep.28122 · Cited by 82
Self-citationBizzaro, N., Covini, G., Rosina, F., Muratori, P., Tonutti, E., Villalta, D., Pesente, F., Alessio, M. G., Tampoia, M., Antico, A., et al. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8234-y · Cited by 79
“hepatic bile ducts are targeted by an immune-mediated injury, ultimately leading to liver fibrosis and cirrhosis [1].”
BackgroundSelf-citationTerziroli Beretta-Piccoli, B., Mieli-Vergani, G., & Vergani, D. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.004 · Cited by 61
Metadata
- Authors
- Selmi, C., Zuin, M., & Gershwin, M. E.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 49
- Issue
- 3
- Pages
- 451-460
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1989400873
- Cited by
- 50
- References
- 26
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.